Get the Stockscreener App
25.05
4.72%
1.13
After Hours:
25.05
Damora Therapeutics Inc stock is traded at $25.05, with a volume of 142.54K.
It is up +4.72% in the last 24 hours and up +0.00% over the past month.
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
See More
Previous Close:
$23.92
Open:
$24.63
24h Volume:
142.54K
Relative Volume:
2.32
Market Cap:
$1.51B
Revenue:
-
Net Income/Loss:
$-209.84M
P/E Ratio:
-5.4814
EPS:
-4.57
Net Cash Flow:
$-6.73M
1W Performance:
+18.44%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$23.54
$26.11
1-Week Range:
$16.50
$26.11
52-Week Range:
$16.50
$27.60
Damora Therapeutics Inc Stock (DMRA) Company Profile
Name
Damora Therapeutics Inc
Sector
Industry
Phone
(781) 281-9020
Address
221 CRESCENT STREET, WALTHAM
Compare DMRA vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMRA
Damora Therapeutics Inc
|
25.05 | 1.44B | 0 | -209.84M | -6.73M | -4.57 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Damora Therapeutics Inc Stock (DMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-17-26 | Initiated | UBS | Buy |
| Jan-07-26 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Guggenheim | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | BofA Securities | Buy |
| Nov-23-20 | Initiated | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | SVB Leerink | Outperform |
View All
Damora Therapeutics Inc Stock (DMRA) Latest News
This Vertiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Trends and Sentiment 2026 - MarketBeat
Evercore ISI initiates Damora Therapeutics stock with outperform - Investing.com
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
DMRA Ownership | DAMORA THERAPEUTICS INC (NASDAQ:DMRA) - ChartMill
Damora names Jennifer Jarrett CEO, adds two board members By Investing.com - Investing.com Australia
DMRA Income Statement | DAMORA THERAPEUTICS INC (NASDAQ:DMRA) - ChartMill
Damora Therapeutics stock surges on new CEO appointment - Investing.com
Damora Therapeutics Appoints Jennifer Jarrett as CEO, Expands Board with Biotech Leaders to Advance mutCALR-Driven MPN Therapies - Minichart
Damora Therapeutics, Inc. Announces Executive and Board Changes - marketscreener.com
Damora Therapeutics Announces Major Leadership and Board Overhaul - TipRanks
Damora names Jennifer Jarrett CEO; Michael Landsittel and Cameron Turtle join board - TradingView
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors - Bitget
Damora Therapeutics appoints biotechnology leader Jennifer Jarrett as president and chief executive officer - marketscreener.com
Damora names Jennifer Jarrett CEO, adds two board members - Investing.com
Discontinued operations of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Damora Therapeutics, Inc. Common Stock (DMRA) Expected to Announce Earnings on Monday - Defense World
Damora Therapeutics, Inc. Common Stock (DMRA) Earnings Date and Reports 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Chart and Price History 2026 - MarketBeat
Damora Therapeutics, Inc.(NasdaqCM:DMRA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Damora Therapeutics, Inc. Common Stock (DMRA) Institutional Ownership 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) Insider Trading Activity 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) 10K Form and SEC Filings 2026 - MarketBeat
Leerink cuts Damora Therapeutics stock price target to $55 on timing - Investing.com UK
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Gap UpHere's What Happened - MarketBeat
Damora Therapeutics, Inc. 2026 Annual Report: Pipeline Overview, Business Strategy, Risks, and Recent Developments - Minichart
Damora Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | DMRA | US36322Q2066 - marketscreener.com
Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Trading Down 10%What's Next? - MarketBeat
DMRA Stock Price, Quote & Chart | DAMORA THERAPEUTICS INC (NASDAQ:DMRA) - ChartMill
DMRA Technical Analysis | Trend, Signals & Chart Patterns | DAMORA THERAPEUTICS INC (NASDAQ:DMRA) - ChartMill
Damora Therapeutics 10-K: $0 Revenue, $(209.8)M Net Loss - TradingView
Damora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
DMRA Stock Price and Chart — NASDAQ:DMRA - TradingView
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Price, News & Analysis - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) Short Interest & Short Float | Updated Mar 2026 - MarketBeat
Damora Therapeutics, Inc. Common Stock (DMRA) Stock Forecast and Price Target 2026 - MarketBeat
Galecto rebrands as Damora Therapeutics, begins Nasdaq trading - Investing.com Nigeria
Non-controlling/minority interest of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Damora Therapeutics, Inc. Stock Chart | NASDAQ: DMRA Stock Price - Bitget
Taxes of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Net income before discontinued operations of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Inventory turnover of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Return on invested capital % of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Inventory turnover of Damora Therapeutics, Inc. – BOATS:DMRA - TradingView
Discontinued operations of Damora Therapeutics, Inc. – BOATS:DMRA - TradingView
After tax other income/expense of Damora Therapeutics, Inc. – BOATS:DMRA - TradingView
DMRA Stock Price and Chart — BOATS:DMRA - TradingView
Price to cash flow ratio of Damora Therapeutics, Inc. – NASDAQ:DMRA - TradingView
Damora Therapeutics Inc Stock (DMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):